Current research on novel therapeutics for AD focuses on targeting various molecular mechanisms and phenomena including amyloid deposition [7], astrogliosis [16], tau protein hyperphosphorylation and accumulation [7], neuronal dystrophy [17], oxidative stress [18], biometal dyshomeostasis, and reduced acetylcholine (ACh) levels [1,2]. The gene discussed is MAPT; the disease is Alzheimer disease.